Tanya Siddiqi, MD
Hematology · Duarte, CANPI 1467408948
Payments from drug & device makers
Across 536 payments — averaging $35,097 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$7.8M
- AbbVie$4.6M
- Beigene, Ltd.$2.4M
- E.r. Squibb & Sons, L.L.C.$2.3M
- TG Therapeutics, Inc.$452K
- Pharmacyclics LLC, An Abbvie Company$427K
- plus $862K from 19 others
Across 4 payments — averaging $1478.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$6K
- Pharmacyclics LLC, An Abbvie Company$61
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 71 | $7,822,311 |
| AbbVie | 117 | $4,584,558 |
| Beigene, Ltd. | 88 | $2,388,751 |
| E.r. Squibb & Sons, L.L.C. | 16 | $2,275,239 |
| TG Therapeutics, Inc. | 26 | $451,822 |
| Pharmacyclics LLC, An Abbvie Company | 80 | $427,040 |
| Acerta Pharma LLC | 5 | $251,525 |
| Beone Medicines Ltd. | 12 | $203,488 |
| Gilead | 13 | $189,426 |
| Incyte Corporation | 4 | $58,496 |
| AstraZeneca(2 entities) | 58 | $53,381 |
| F. Hoffmann-la Roche AG | 4 | $28,866 |
| Janssen Research & Development, LLC | 2 | $23,483 |
| Beigene USA, Inc. | 16 | $22,403 |
| Boehringer Ingelheim | 1 | $13,115 |
| Seagen Inc. | 4 | $7,025 |
| Genmab U.S., Inc. | 5 | $5,573 |
| Innate Pharma, Inc | 1 | $2,400 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| Merck | 2 | $239 |
| Genentech USA, Inc. | 4 | $195 |
| Morphosys, US Inc. | 1 | $138 |
| Johnson & Johnson | 3 | $85 |
| Astrazeneca UK Limited | 1 | $45 |
| Pfizer | 1 | $14 |
How this compares
$18,812,019 in reported general payments places this provider in the 95th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Alex HerreraDuarte$50.9M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
- Haris AliDuarte$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.